Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | ACHE | P22303 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590605 | 1.00 | BCHE (0.79) | BCHEKMT2AACHEKDM4EMAPT | |
| SCHEMBL4245372 | 1.00 | BCHE (0.79) | BCHEKMT2AACHEKDM4EMAPT | |
| SCHEMBL4251359 | 1.00 | BCHE (0.79) | BCHEKMT2AACHEKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28933519 | 0.99 | BCHE (0.77) | BCHEKMT2AACHEKDM4EMAPT | |
| Bromide SCHEMBL5898942 | 0.99 | BCHE (0.77) | BCHEKMT2AACHEKDM4EMAPT | |
| Bromide SCHEMBL5898925 | 0.99 | BCHE (0.77) | BCHEKMT2AACHEKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28933498 | 0.92 | KDM4E (0.73) | BCHEKMT2AACHEKDM4EMAPT | |
| SCHEMBL28933497 | 0.90 | KDM4E (0.78) | BCHEKMT2AACHEKDM4EMAPT | |
| Tetrahydropapaverine SCHEMBL251076 | 0.89 | BCHE (0.79) | BCHEKDM4EMAPTPKM | |
| Tetrahydropapaverine SCHEMBL6398843 | 0.89 | BCHE (0.79) | BCHEKDM4EMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536584-B | Synthesis method of norlinderane hydrochloride | 珠海润都制药股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-115536584-A | Synthetic method of higenamine hydrochloride | 珠海润都制药股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115536584-B | Synthesis method of norlinderane hydrochloride | 珠海润都制药股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-115260094-B | New method for synthesizing norlinderane hydrochloride | 珠海润都制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115536584-A | Synthetic method of higenamine hydrochloride | 珠海润都制药股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021115413-A1 | NEUROMUSCULAR-BLOCKING DRUG AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115413-A1 | NEUROMUSCULAR-BLOCKING DRUG AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| CN-110156684-A | A kind of synthesis technology of demethyl coclaurine and its pharmaceutical salts | 珠海市柏瑞医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-103554022-A | Synthetic method of higenamine hydrochloride | SUZHOU UUGENE BIOPHARMA CO LTD | 2014-02-05 | — | — | CN | disclosed |
| CN-103554022-A | Synthetic method of higenamine hydrochloride | SUZHOU UUGENE BIOPHARMA CO LTD | 2014-02-05 | — | — | CN | disclosed |
| EP-2305260-A1 | Psychotropic agent and health food containing benzylisoquinoline derivative | Education Center of Traditional Chinese Medicine Co. (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-1379523-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002076979-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-03 | — | — | WO | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
| EP-1129076-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000029380-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2000-05-25 | — | — | WO | disclosed |
| US-5981521-A | USEFUL FOR TREATING VARIOUS HORMONE DEPENDENT DISEASES, INCLUDING PROSTATE CANCER, ENDOMETRIOSIS, UTERINE FIBROIDS, PRECOCIOUS PUBERTY, BENIGN PROSTATE HYPERTROPY AND IN VITRO FERTILIZATION | ABBOTT LABORATORIES (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0617022-A1 | 6,7, dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | BCHE 2321/4885KMT2A 1396/4885ACHE 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.